Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Peffault de Latour, Régis  [Clear All Filters]
2024
de Latour RPeffault, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh MM, Panse JPeter. Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024.
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.
de Latour RPeffault, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994-1008.
Patriquin CJ, Bogdanovic A, Griffin M, Kelly RJ, Maciejewski JP, Mulherin B, de Latour RPeffault, Röth A, Selvaratnam V, Szer J, et al. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Adv Ther. 2024.
2023
Hakkarainen M, Kaaja I, Douglas SPM, Vulliamy TJ, Dokal I, Soulier J, Larcher L, de Latour RPeffault, Leblanc TM, de Fontbrune FSicre, et al. The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia. Blood. 2023.
Höchsmann B, de Latour RPeffault, Hill A, Röth A, Devos T, Patriquin CJ, Chou W-C, Jain D, Zu K, Wu C, et al. Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry. Ann Hematol. 2023.
2021
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FSicre, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021.
Longval T, Galimard J-E, Leprêtre A-C, Suarez F, Amiranoff D, Cazaux M, Kaphan E, Michonneau D, Dhedin N, Coman T, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 2021.
2020
de Latour RPeffault, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MSheng. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. Ann Hematol. 2020.
de Latour RPeffault, Chevallier P, Blaise D, Alami S, Levy-Bachelot L, Allavoine T, Tadmouri A, Blomkvist J, Duhamel A, Srour M, et al. Clinical and Economic Impact of Treated CMV Infection in Adult CMV-seropositive Patients after Allogeneic Hematopoietic Cell Transplantation. J Med Virol. 2020.
Chevillon F, Clappier E, Arfeuille C, Cayuela J-M, Dalle J-H, Kim R, Caye A, Chalas C, Abdo C, Drouineaud V, et al. Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia. Blood. 2020.
2019
de Latour RPeffault, Chevret S, Ruggeri ALisa, Suarez F, Souchet L, Michonneau D, de Fontbrune FSicre, Coman T, Dhedin N, Rubio MThérèse, et al. Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. Blood. 2019.
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.
2015
O'Meara A, Boukouaci W, Robin M, Xhaard A, Fortier C, Marzais F, de Fontbrune FSicre, de Latour RPeffault, Charron D, Socié G, et al. GLCCI1 and GR genetic diversity and response to glucocorticoid-based treatment of graft-versus-host disease. Biol Blood Marrow Transplant. 2015.
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, et al. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.
de Fontbrune FSicre, de Latour RPeffault. Paroxysmal Nocturnal Hemoglobinuria and Hematopoietic Stem Cell Transplantation: better results in 2015?. Leuk Lymphoma. 2015:1-5.
2014
Itzykson R, Robin M, Moins-Teisserenc H, Delord M, Busson M, Xhaard A, de Fontbrune FSicre, de Latour RPeffault, Toubert A, Socié G. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2014.
Loschi M, Porcher R, de Latour RPeffault, Vanneaux V, Robin M, Xhaard A, de Fontebrune FSicre, Larghero J, Socié G. High Number of memory T cells is associated with higher risk Of acute GVHD after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
Glauzy S, Soret J, Fournier I, Douay C, Moins-Teisserenc H, de Latour RPeffault, Maki G, Robin M, Socié G, Toubert A, et al. Impact of acute and chronic Graft-vs-Host Disease on human B-cell generation and replication. Blood. 2014.
Schlemmer F, Chevret S, Lorillon G, De Bazelaire C, de Latour RPeffault, Meignin V, Michallet M, Hermet E, Wyplosz B, Houdouin V, et al. Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respir Med. 2014.